Govt. releases DRDO’s COVID drug for emergency use
The Hindu
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) — developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad — was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan. “One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence Ministry statement said. An anti-COVID-19 therapeutic application of the drug 2-DG has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a DRDO lab along with DRL.More Related News